Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$148.53
-0.7%
$155.83
$143.13
$175.97
$357.92B0.537.39 million shs9.60 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$732.20
-1.8%
$763.89
$370.68
$800.78
$695.71B0.343.04 million shs2.05 million shs
Novartis AG stock logo
NVS
Novartis
$98.35
+1.1%
$97.95
$92.19
$108.78
$201.03B0.541.55 million shs2.23 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.26
-0.2%
$27.07
$25.23
$40.37
$148.70B0.6141.89 million shs24.50 million shs
Roche Holding AG stock logo
RHHBY
Roche
$30.54
-2.2%
$32.02
$29.95
$40.48
N/A0.392.41 million shs3.14 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.30%+3.54%-3.65%-5.92%-8.63%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+1.96%-0.13%-3.24%+17.61%+94.50%
Novartis AG stock logo
NVS
Novartis
+2.29%+4.40%+1.10%-9.54%-3.28%
Pfizer Inc. stock logo
PFE
Pfizer
+0.23%+2.45%-3.80%-7.09%-34.05%
Roche Holding AG stock logo
RHHBY
Roche
+1.07%+2.16%-0.26%-11.45%-21.21%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.9007 of 5 stars
3.23.04.23.93.02.51.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8445 of 5 stars
2.44.02.54.02.42.53.1
Novartis AG stock logo
NVS
Novartis
2.6977 of 5 stars
2.13.02.50.03.00.02.5
Pfizer Inc. stock logo
PFE
Pfizer
4.995 of 5 stars
3.25.04.24.83.11.73.1
Roche Holding AG stock logo
RHHBY
Roche
2.8547 of 5 stars
3.02.01.70.03.20.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8618.40% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.05-0.57% Downside
Novartis AG stock logo
NVS
Novartis
2.25
Hold$115.0016.93% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3338.36% Upside
Roche Holding AG stock logo
RHHBY
Roche
2.00
Hold$40.0030.98% Upside

Current Analyst Ratings

Latest JNJ, RHHBY, NVS, PFE, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
Novartis AG stock logo
NVS
Novartis
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$114.00 ➝ $116.00
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/15/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.20$13.61 per share10.91$28.57 per share5.20
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.39$7.64 per share95.89$11.44 per share64.00
Novartis AG stock logo
NVS
Novartis
$45.44B4.42$11.49 per share8.56$22.87 per share4.30
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.54$2.98 per share8.82$15.81 per share1.66
Roche Holding AG stock logo
RHHBY
Roche
$65.37BN/A$3.07 per share9.95$4.91 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.2613.562.4645.26%36.43%15.01%7/18/2024 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80126.2439.581.5915.36%51.22%9.94%4/30/2024 (Confirmed)
Novartis AG stock logo
NVS
Novartis
$14.85B$7.1813.7012.391.5529.83%29.90%12.97%7/16/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3672.949.481.183.62%10.88%4.91%5/1/2024 (Confirmed)
Roche Holding AG stock logo
RHHBY
Roche
$12.81BN/A0.0011.444.50N/AN/AN/AN/A

Latest JNJ, RHHBY, NVS, PFE, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
1/30/202412/31/2023
Novartis AG stock logo
NVS
Novartis
$1.64$1.53-$0.11-$1.08$11.69 billion$11.42 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.20%+5.70%29.68%63 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.71%+15.15%89.66%10 Years
Novartis AG stock logo
NVS
Novartis
$2.432.47%+4.26%33.84%4 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.40%+2.57%466.67%15 Years
Roche Holding AG stock logo
RHHBY
Roche
$0.882.88%N/AN/AN/A

Latest JNJ, RHHBY, NVS, PFE, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/10/20246/14/2024
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
3/1/2024
Novartis AG stock logo
NVS
Novartis
annual$3.77723.1%3/7/20243/8/20243/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.38
1.16
0.91
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73
Novartis AG stock logo
NVS
Novartis
0.39
1.15
0.93
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69
Roche Holding AG stock logo
RHHBY
Roche
0.75
1.35
1.04

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novartis AG stock logo
NVS
Novartis
13.12%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Roche Holding AG stock logo
RHHBY
Roche
N/A

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novartis AG stock logo
NVS
Novartis
0.01%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Roche Holding AG stock logo
RHHBY
Roche
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.41 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable
Novartis AG stock logo
NVS
Novartis
76,0572.04 billion2.04 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable
Roche Holding AG stock logo
RHHBY
Roche
103,605N/AN/ANot Optionable

JNJ, RHHBY, NVS, PFE, and LLY Headlines

SourceHeadline
Roche cuts drug pipeline in effort to revitalise businessRoche cuts drug pipeline in effort to revitalise business
ft.com - April 24 at 4:02 PM
Hookipa Received FDA Clearance For HB-700 For Treatment Of KRAS-Mutated CancersHookipa Received FDA Clearance For HB-700 For Treatment Of KRAS-Mutated Cancers
markets.businessinsider.com - April 24 at 11:01 AM
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
benzinga.com - April 24 at 11:01 AM
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 SalesRoche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
zacks.com - April 24 at 10:16 AM
Roche Q1 Group Sales Down 6%; Confirms 2024 Outlook - Quick FactsRoche Q1 Group Sales Down 6%; Confirms 2024 Outlook - Quick Facts
markets.businessinsider.com - April 24 at 5:06 AM
Swiss pharma giant Roches first-quarter sales edge higher as its emerges from post-Covid-19 slumpSwiss pharma giant Roche's first-quarter sales edge higher as its emerges from post-Covid-19 slump
cnbc.com - April 24 at 1:58 AM
Roche Q1 sales down 6% on forex effect, loss of COVID revenueRoche Q1 sales down 6% on forex effect, loss of COVID revenue
reuters.com - April 24 at 1:14 AM
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
globenewswire.com - April 24 at 1:00 AM
Pharma Stock Roundup: JNJs Q1 Results, LLY, ABBV, RHHBYs Successful Study DataPharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
msn.com - April 19 at 3:11 PM
Roche (RHHBY) Alecensa Wins FDA Nod for Label ExpansionRoche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
zacks.com - April 19 at 11:16 AM
F. Hoffmann-La Roche Ltd: FDA approves Roches Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerF. Hoffmann-La Roche Ltd: FDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
finanznachrichten.de - April 19 at 3:29 AM
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerFDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
finance.yahoo.com - April 19 at 3:29 AM
Roche Announces FDA Approval For AlecensaRoche Announces FDA Approval For Alecensa
markets.businessinsider.com - April 19 at 3:29 AM
FDA approves Roches Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerFDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
globenewswire.com - April 19 at 1:00 AM
FDA Approves Genentechs Alecensa For ALK-positive Early-Stage Lung CancerFDA Approves Genentech's Alecensa For ALK-positive Early-Stage Lung Cancer
markets.businessinsider.com - April 18 at 10:08 PM
FDA Approves Genentechs Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung CancerFDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
businesswire.com - April 18 at 4:35 PM
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MSGenentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
finance.yahoo.com - April 17 at 10:38 AM
Celebration Obstetrics & Gynecology Now Accepting Partners Direct Health InsuranceCelebration Obstetrics & Gynecology Now Accepting Partner's Direct Health Insurance
finance.yahoo.com - April 16 at 1:44 PM
Roches Lymphoma Drug With Chemo Extends Survival In Pretreated PatientsRoche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
msn.com - April 15 at 3:19 PM
Roches (RHHBY) Combination Therapy Meets Goal in Lymphoma StudyRoche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
zacks.com - April 15 at 8:36 AM
Genentechs Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO StudyGenentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
businesswire.com - April 15 at 1:10 AM
[Ad hoc announcement pursuant to Art. 53 LR] Roches Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study[Ad hoc announcement pursuant to Art. 53 LR] Roche's Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
globenewswire.com - April 15 at 1:00 AM
Guru Fundamental Report for RHHBYGuru Fundamental Report for RHHBY
nasdaq.com - April 13 at 12:02 AM
Why Roche Holdings Stock Popped TodayWhy Roche Holdings Stock Popped Today
fool.com - April 11 at 6:33 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Novartis logo

Novartis

NYSE:NVS
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Roche logo

Roche

OTCMKTS:RHHBY
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.